ZymoGenetics Inc. reported "positive survival data" from a clinical trial of its drug targeting skin cancer.
The Seattle biotech (NASDAQ: ZGEN), which is being bought by Bristol-Myers Squibb Co. for $885 million, reported that a clinical trial of its Interleukin 21 (IL-21) indicated patients' overall survival was 12.4 months.
“The median overall survival of 12.4 months in the Phase 2 study with IL-21 in advanced melanoma patients is very encouraging,” said Dr. Eleanor Ramos, senior vice president and chief medical officer of ZymoGenetics, in a statement.
ZymoGenetics said the clinical trial was conducted on 40 Canadian patients with melanoma.
Here's a link to ZymoGenetics' release on the trial.
The Seattle biotech (NASDAQ: ZGEN), which is being bought by Bristol-Myers Squibb Co. for $885 million, reported that a clinical trial of its Interleukin 21 (IL-21) indicated patients' overall survival was 12.4 months.
“The median overall survival of 12.4 months in the Phase 2 study with IL-21 in advanced melanoma patients is very encouraging,” said Dr. Eleanor Ramos, senior vice president and chief medical officer of ZymoGenetics, in a statement.
ZymoGenetics said the clinical trial was conducted on 40 Canadian patients with melanoma.
Here's a link to ZymoGenetics' release on the trial.
Read more: ZymoGenetics reports positive skin cancer drug results - Puget Sound Business Journal (Seattle)
**Published in "Business Journal"
No comments:
Post a Comment